Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial)

Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, Spriewald B, Hanoun M, Martin S, Schwab K, Knaden J, Marx J, Wethmar K, Sauer T, Berdel WE, Lenz G, Dugas M, Goekbuget N, Brueggemann M, Raffel S (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: AMER SOC HEMATOLOGY

City/Town: WASHINGTON

Conference Proceedings Title: BLOOD

DOI: 10.1182/blood-2021-145553

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Münster Germany (DE) Technische Universität Dresden Germany (DE) Albert-Ludwigs-Universität Freiburg Germany (DE) Universitätsklinikum Jena Germany (DE) Heinrich-Heine-Universität Düsseldorf Germany (DE) Universitätsklinikum Augsburg Germany (DE) Klinikum Chemnitz Germany (DE) Universitätsklinikum Essen Germany (DE) Robert-Bosch-Krankenhaus Germany (DE) Rheinische Friedrich-Wilhelms-Universität Bonn Germany (DE) Goethe-Universität Frankfurt am Main Germany (DE) Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Ruprecht-Karls-Universität Heidelberg Germany (DE)

How to cite

APA:

Stelljes, M., Alakel, N., Waesch, R., Scholl, S., Nachtkamp, K., Rank, A.,... Raffel, S. (2021). Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial). In BLOOD. WASHINGTON: AMER SOC HEMATOLOGY.

MLA:

Stelljes, Matthias, et al. "Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial)." Proceedings of the BLOOD WASHINGTON: AMER SOC HEMATOLOGY, 2021.

BibTeX: Download